arrow

From NeuroLex

Jump to: navigation, search



Metformin

Name: Metformin
Description: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289) Pharmacology: Metformin is an antihyperglycemic agent, which improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Metformin is not chemically or pharmacologically related to any other classes of oral antihyperglycemic agents. Unlike sulfonylureas, metformin does not produce hypoglycemia in either patients with type 2 diabetes or normal subjects and does not cause hyperinsulinemia. With metformin therapy, insulin secretion remains unchanged while fasting insulin levels and daylong plasma insulin response may actually decrease. Mechanism of action: Metformin's pharmacologic mechanisms of action are different from other classes of oral antihyperglycemic agents. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. Drug type: Approved. Small Molecule. Drug category: Hypoglycemic Agents
Synonym(s): Metformin HCL, metformin hydrochloride, Apo-Metformin, Fortamet, Gen-Metformin, Glucophage, Glucophage XR, Glycon, Novo-Metformin, Nu-Metformin, Riomet
Has role: Drug
Super-category: Molecular entity
URL: http://www.drugbank.ca/drugs/DB00331
*Id: CHEBI:6801
Related to: 5'-AMP-activated protein kinase subunit beta-1
Link to OWL / RDF: Download this content as OWL/RDF




bookmark

*Note: Neurolex imports many terms and their ids from existing community ontologies, e.g., the Gene Ontology. Neurolex, however, is a dynamic site and any content beyond the identifier should not be presumed to reflect the content or views of the source ontology. Users should consult with the authoritative source for each ontology for current information.

Facts about MetforminRDF feed
Commenttaken from DrugBank
CurationStatusuncurated  +
CuratorAb  +
DefiningCitationhttp://www.drugbank.ca/drugs/DB00331  +
DefinitionA biguanide hypoglycemic agent used in the A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289) Pharmacology: Metformin is an antihyperglycemic agent, which improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Metformin is not chemically or pharmacologically related to any other classes of oral antihyperglycemic agents. Unlike sulfonylureas, metformin does not produce hypoglycemia in either patients with type 2 diabetes or normal subjects and does not cause hyperinsulinemia. With metformin therapy, insulin secretion remains unchanged while fasting insulin levels and daylong plasma insulin response may actually decrease. Mechanism of action: Metformin's pharmacologic mechanisms of action are different from other classes of oral antihyperglycemic agents. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. Drug type: Approved. Small Molecule. Drug category: Hypoglycemic Agents lecule. Drug category: Hypoglycemic Agents
Has roleDrug  +
IdCHEBI:6801  +
LabelMetformin  +
ModifiedDate12 August 2014  +
RelatedTo5'-AMP-activated protein kinase subunit beta-1  +
SuperCategoryMolecular entity  +
SynonymMetformin HCL  +, metformin hydrochloride  +, Apo-Metformin  +, Fortamet  +, Gen-Metformin  +, Glucophage  +, Glucophage XR  +, Glycon  +, Novo-Metformin  +, Nu-Metformin  +, and Riomet  +